Peptide Partners LLC
Has Peptide Partners LLC received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Peptide Partners LLC a warning letter naming semaglutide, tirzepatide and retatrutide, dated Aug 24, 2026, with the FDA subject line “Unapproved New Drugs/Misbranded.”
FDA records in this index name Peptide Partners LLC on Aug 24, 2026.
- Type named in FDA records
- Not stated
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Semaglutide, Tirzepatide, Retatrutide
- Latest record
- Aug 24, 2026
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Aug 24, 2026 | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Aug 24, 2026: … in July 2026. Based on our review,“GLP-1 S ( Semaglutide ),” “GLP-2 T (Tirzepatide),” “GLP-3 Reta … Violations Based on a review of your website, “GLP-1 S ( Semaglutide ),” “GLP-2 T (Tirzepatide),” “GLP-3 Reta … but may not be limited to, the following: GLP-1 S ( Semaglutide ) On the webpage … Full letter
Drug recalls
No openFDA drug recall reports in this index.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.